Lars Galonska

  • Citations Per Year
Learn More
Patients suffering from high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) secondary to MDS (sAML) are characterized by poor response to conventional cytotoxic chemotherapy. The purpose of our prospective single-center study was to examine the safety and efficacy of an allogeneic hematopoietic stem cell transplantation (HSCT)(More)
Bispecific tetravalent antibodies (TandAb) directed against the B cell surface marker CD19 and activating receptors on T or NK cells (CD19 × CD3 or CD19 × CD16) have shown promising effects in vitro and in preclinical studies. Here, we examine the cytotoxic efficacy of T and NK cells from patients with B cell Non-Hodgkin′s Lymphoma (NHL) against B-lymphoma(More)
Plerixafor is a reversible CXCR4 antagonist that leads to a rapid release of hematopoietic stem and progenitor cells (HPSCs) from the bone marrow into the peripheral blood by interfering with the CXCL12-CXCR4 interaction. Based on two multicenter phase III studies, plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) was approved by(More)
  • 1